ARTICLE

FindCenter AddIcon

MDMA’s Journey from Molly to Medicine

By Alfonso Serrano — 2017

MDMA-assisted psychotherapy readies for phase III trials, a last step before possible prescription use in PTSD patients.

Read on www.scientificamerican.com

FindCenter Post-Image

It’s Time to Start Studying the Downside of Psychedelics

Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong.

Article
Shayla Love
2022
FindCenter AddIcon
FindCenter Post-Image

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression

The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).

Article
Yasemin Saplakoglu
2019
FindCenter AddIcon
FindCenter Post-Image

Ketamine Therapy Is Going Mainstream. Are We Ready?

The mind-altering drug has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.

Article
Emily Witt
2021
FindCenter AddIcon
FindCenter Post-Image

Integration, Rippling

In the deep space of the psychedelic experience exists a teaching on unity principle and belonging with the earth.

Article
Francoise Bourzant
2020
FindCenter AddIcon
FindCenter Post-Image

Inside The Movement To Decolonize Psychedelic Pharma

As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.

Article
Carolyn Gregoire
2020
FindCenter AddIcon
FindCenter Post-Image

Experimental Treatments Changed the Course of the AIDS Epidemic; We Need the Same Approach to Mental Illness Today | Commentary

Demand from patients seeking help for their mental illnesses has led to underground use in a way that parallels black markets in the AIDS pandemic. This underground use has been most perilous for people of color, who face greater stigma and legal risks due to the War on Drugs.

Article
Monnica Williams, Morgan Campbell
2021
FindCenter AddIcon
FindCenter Post-Image

Meet the Psychologist Using Psychedelics to Treat Racial Trauma

People of color are dealing with racism all the time, in large and small ways, and even dealing with racism in healthcare, even dealing with racism in therapy.

Article
Robin Donovan
2021
FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

Article
Xinyuan Chen, Mackenzie Bullard, Christy Duan, Jamilah R. George, Terence Ching, Stephanie Kilpatrick, Jordan Sloshower, Monnica Williams
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

Article
Monnica T. Williams
2018
FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

Article
Hannah Sabourin
2021
FindCenter AddIcon

EXPLORE TOPIC

MDMA